Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that six varieties of the Company’s products were included in the First Edition of Catalogue of Medicine for Patients Infected with COVID-19 (the “Catalogue”), which was published by Beijing Health Commission on December 12, 2022.
Ji’an, Jiangxi, China, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that six varieties of the Company’s products were included in the First Edition of Catalogue of Medicine for Patients Infected with COVID-19 (the “Catalogue”), which was published by Beijing Health Commission on December 12, 2022. The included products are Banlangen Granules, Strong Loquat Extract, Pediatric Paracetamol, Vitamin C Yinqiao Tablets, Acetaminophen Tablets and Metamizole Sodium Tablets.
The Catalogue supplements the list of recommended medicine in the Ninth Edition of the National Diagnosis and Treatment Plan. The Catalogue recommends 67 types of traditional Chinese medicine products for six different types of medical symptoms, such as fever and sore throat, and recommends 41 varieties of western medicine products for four types of clinical symptoms, such as cough and expectoration. In addition to hospitals, patients can also purchase medicines included in the Catalogue from channels such as retail pharmacies and e-commerce platforms according to their own needs.
Mr. Gang Lai, Chairman and CEO of Universe Pharmaceuticals INC, commented, “We are pleased to have our products included in the Catalogue. Currently, the order volume of our three products, Banlangen Granules, Strong Loquat Extract and Pediatric Paracetamol, continues to increase. We will optimize the supply chain system to meet the increasing demand and strive to ensure sufficient supply of these three products for people to fight against COVID-19 symptoms.”
About Universe Pharmaceuticals INC
Universe Pharmaceuticals INC, headquartered in Ji’an, Jiangxi, China, is a pharmaceutical producer and distributor in China. The Company specializes in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being. The Company also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Currently, the Company’s products are sold in 30 provinces of China. For more information, visit the company’s website at http://www.universe-pharmacy.com/.
Forward-Looking Statements
All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,”“will,”“expect,”“anticipate,”“aim,”“estimate,”“intend,”“plan,”“believe,”“potential,”“continue,”“is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the U.S. Securities and Exchange Commission.
For more information, please contact:
Ascent Investors Relations LLC
Tina Xiao
President
Phone: 917-609-0333
Email: tina.xiao@ascent-ir.com
